Cargando…
Pembrolizumab‐induced pancytopenia in a patient with squamous cell lung cancer
Immune checkpoint inhibitors (ICIs) are reportedly effective against many kinds of neoplasm, but may be responsible for several kinds of immune‐related adverse events (irAEs). Among these irAEs, the incidence of myelosuppression due to ICIs is relatively low. Corticosteroids are needed to control mo...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7471020/ https://www.ncbi.nlm.nih.gov/pubmed/32767641 http://dx.doi.org/10.1111/1759-7714.13582 |
_version_ | 1783578693725061120 |
---|---|
author | Ueki, Yuriko Suzuki, Manabu Horikawa, Yuriko Watanabe, Hiromu Yamaguchi, Yoh Morita, Chie Tsukada, Akinari Takumida, Hiroshi Kusaba, Yusaku Katsuno, Takashi Tsujimoto, Yoshie Sakamoto, Keita Hashimoto, Masao Terada, Junko Ishii, Satoru Takasaki, Jin Naka, Go Iikura, Motoyasu Izumi, Shinyu Takeda, Yuichiro Hojo, Masayuki Sugiyama, Haruhito |
author_facet | Ueki, Yuriko Suzuki, Manabu Horikawa, Yuriko Watanabe, Hiromu Yamaguchi, Yoh Morita, Chie Tsukada, Akinari Takumida, Hiroshi Kusaba, Yusaku Katsuno, Takashi Tsujimoto, Yoshie Sakamoto, Keita Hashimoto, Masao Terada, Junko Ishii, Satoru Takasaki, Jin Naka, Go Iikura, Motoyasu Izumi, Shinyu Takeda, Yuichiro Hojo, Masayuki Sugiyama, Haruhito |
author_sort | Ueki, Yuriko |
collection | PubMed |
description | Immune checkpoint inhibitors (ICIs) are reportedly effective against many kinds of neoplasm, but may be responsible for several kinds of immune‐related adverse events (irAEs). Among these irAEs, the incidence of myelosuppression due to ICIs is relatively low. Corticosteroids are needed to control most cases of myelosuppression. Here, we report an 88‐year‐old woman with squamous cell lung cancer who was administered pembrolizumab. After five cycles of pembrolizumab, she developed severe pancytopenia. The pancytopenia improved under observation without steroid administration after cessation of pembrolizumab. During recovery from this irAE, the patient also maintained long‐term antitumor efficacy. KEY POINTS: SIGNIFICANT FINDINGS OF THE STUDY: There are several kinds of immune‐related adverse events. We encountered a case of pembrolizumab‐induced pancytopenia with squamous cell lung cancer. WHAT THIS STUDY ADDS: Corticosteroids are needed to control most cases of myelosuppression induced by ICIs, but pancytopenia induced by pembrolizumab in our case improved without steroids. |
format | Online Article Text |
id | pubmed-7471020 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley & Sons Australia, Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-74710202020-09-09 Pembrolizumab‐induced pancytopenia in a patient with squamous cell lung cancer Ueki, Yuriko Suzuki, Manabu Horikawa, Yuriko Watanabe, Hiromu Yamaguchi, Yoh Morita, Chie Tsukada, Akinari Takumida, Hiroshi Kusaba, Yusaku Katsuno, Takashi Tsujimoto, Yoshie Sakamoto, Keita Hashimoto, Masao Terada, Junko Ishii, Satoru Takasaki, Jin Naka, Go Iikura, Motoyasu Izumi, Shinyu Takeda, Yuichiro Hojo, Masayuki Sugiyama, Haruhito Thorac Cancer Case Reports Immune checkpoint inhibitors (ICIs) are reportedly effective against many kinds of neoplasm, but may be responsible for several kinds of immune‐related adverse events (irAEs). Among these irAEs, the incidence of myelosuppression due to ICIs is relatively low. Corticosteroids are needed to control most cases of myelosuppression. Here, we report an 88‐year‐old woman with squamous cell lung cancer who was administered pembrolizumab. After five cycles of pembrolizumab, she developed severe pancytopenia. The pancytopenia improved under observation without steroid administration after cessation of pembrolizumab. During recovery from this irAE, the patient also maintained long‐term antitumor efficacy. KEY POINTS: SIGNIFICANT FINDINGS OF THE STUDY: There are several kinds of immune‐related adverse events. We encountered a case of pembrolizumab‐induced pancytopenia with squamous cell lung cancer. WHAT THIS STUDY ADDS: Corticosteroids are needed to control most cases of myelosuppression induced by ICIs, but pancytopenia induced by pembrolizumab in our case improved without steroids. John Wiley & Sons Australia, Ltd 2020-08-07 2020-09 /pmc/articles/PMC7471020/ /pubmed/32767641 http://dx.doi.org/10.1111/1759-7714.13582 Text en © 2020 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Case Reports Ueki, Yuriko Suzuki, Manabu Horikawa, Yuriko Watanabe, Hiromu Yamaguchi, Yoh Morita, Chie Tsukada, Akinari Takumida, Hiroshi Kusaba, Yusaku Katsuno, Takashi Tsujimoto, Yoshie Sakamoto, Keita Hashimoto, Masao Terada, Junko Ishii, Satoru Takasaki, Jin Naka, Go Iikura, Motoyasu Izumi, Shinyu Takeda, Yuichiro Hojo, Masayuki Sugiyama, Haruhito Pembrolizumab‐induced pancytopenia in a patient with squamous cell lung cancer |
title | Pembrolizumab‐induced pancytopenia in a patient with squamous cell lung cancer |
title_full | Pembrolizumab‐induced pancytopenia in a patient with squamous cell lung cancer |
title_fullStr | Pembrolizumab‐induced pancytopenia in a patient with squamous cell lung cancer |
title_full_unstemmed | Pembrolizumab‐induced pancytopenia in a patient with squamous cell lung cancer |
title_short | Pembrolizumab‐induced pancytopenia in a patient with squamous cell lung cancer |
title_sort | pembrolizumab‐induced pancytopenia in a patient with squamous cell lung cancer |
topic | Case Reports |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7471020/ https://www.ncbi.nlm.nih.gov/pubmed/32767641 http://dx.doi.org/10.1111/1759-7714.13582 |
work_keys_str_mv | AT uekiyuriko pembrolizumabinducedpancytopeniainapatientwithsquamouscelllungcancer AT suzukimanabu pembrolizumabinducedpancytopeniainapatientwithsquamouscelllungcancer AT horikawayuriko pembrolizumabinducedpancytopeniainapatientwithsquamouscelllungcancer AT watanabehiromu pembrolizumabinducedpancytopeniainapatientwithsquamouscelllungcancer AT yamaguchiyoh pembrolizumabinducedpancytopeniainapatientwithsquamouscelllungcancer AT moritachie pembrolizumabinducedpancytopeniainapatientwithsquamouscelllungcancer AT tsukadaakinari pembrolizumabinducedpancytopeniainapatientwithsquamouscelllungcancer AT takumidahiroshi pembrolizumabinducedpancytopeniainapatientwithsquamouscelllungcancer AT kusabayusaku pembrolizumabinducedpancytopeniainapatientwithsquamouscelllungcancer AT katsunotakashi pembrolizumabinducedpancytopeniainapatientwithsquamouscelllungcancer AT tsujimotoyoshie pembrolizumabinducedpancytopeniainapatientwithsquamouscelllungcancer AT sakamotokeita pembrolizumabinducedpancytopeniainapatientwithsquamouscelllungcancer AT hashimotomasao pembrolizumabinducedpancytopeniainapatientwithsquamouscelllungcancer AT teradajunko pembrolizumabinducedpancytopeniainapatientwithsquamouscelllungcancer AT ishiisatoru pembrolizumabinducedpancytopeniainapatientwithsquamouscelllungcancer AT takasakijin pembrolizumabinducedpancytopeniainapatientwithsquamouscelllungcancer AT nakago pembrolizumabinducedpancytopeniainapatientwithsquamouscelllungcancer AT iikuramotoyasu pembrolizumabinducedpancytopeniainapatientwithsquamouscelllungcancer AT izumishinyu pembrolizumabinducedpancytopeniainapatientwithsquamouscelllungcancer AT takedayuichiro pembrolizumabinducedpancytopeniainapatientwithsquamouscelllungcancer AT hojomasayuki pembrolizumabinducedpancytopeniainapatientwithsquamouscelllungcancer AT sugiyamaharuhito pembrolizumabinducedpancytopeniainapatientwithsquamouscelllungcancer |